Theriva Biologics, Inc. (TOVX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87164U5083
Theriva Biologics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -24.05 m USD |
| EBIT | -23.97 m USD |
| Net income | -23.74 m USD |
| Diluted EPS – continuing operations | -2.08 USD |
Full history since 1993, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Theriva Biologics, Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
More stocks
- Enveric Biosciences, Inc. (ENVB)
- INNO HOLDINGS INC. (INHD)
- VSEE HEALTH, INC. (VSEE)
- Data Storage Corp (DTST)
- Getty Images Holdings, Inc. (GETY)
- ENDRA Life Sciences Inc. (NDRA)
- LataMed AI Corp. (LMED)
- Chinhung International Inc (002785.KS)
- AiXin Life International, Inc. (AIXN)
- Saker Aviation Services, Inc. (SKAS)
- Lantern Pharma Inc. (LTRN)
- Financial Gravity Companies, Inc. (FGCO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.